<DOC>
	<DOCNO>NCT01829893</DOCNO>
	<brief_summary>To compare relative bioavailability pharmacokinetic characteristic newly single pill combination finasteride tamsulosin conventional combination finasteride tamsulosin healthy subject single dose , randomize , open-label , 2-sequence -2period crossover study .</brief_summary>
	<brief_title>PK Comparison GL2701 With Finasteride Tamsulosin Combination</brief_title>
	<detailed_description>This single dose , open label , balance , randomize , two-treatment , two-period , two-sequence , crossover study conduct compare relative bioavailability pharmacokinetic characteristic newly develop formulation conventional formulation healthy subject . For , single-center , randomize , single-dose , open-label , 2-period 2-sequence crossover study 14-day washout period conduct 26 healthy volunteer . Plasma sample analysis finasteride/tamsulosin collect 48 h drug administration . Participants receive either reference ( combination 0.2mg tamsulosin 5mg finasteride ) test drug formulation ( single pill combination 0.2mg tamsulosin 5mg finasteride ) first period alternative formulation second period . Plasma concentration tamsulosin finasteride determine validate high-performance liquid chromatography couple tandem mass spectrometry detection . Pharmacokinetic parameter , include Cmax AUC , determine noncompartmental analysis . Analysis variance ( ANOVA ) carry use log-transformed Cmax AUC , mean ratio 90 % confidence interval ( CI ) calculate . According regulatory requirement set forth Korea US Food Drug Administration , product meet criterion bioequivalence 90 % CIs mean ratio Cmax AUC within range 0.80 1.25 .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Males age 20 45 year Body weight &gt; 50 kg 18~29 kg/m2 body mass index ( BMI ) Signed date informed consent form meet criteria current FDA KFDA regulation subject acute condition . presence history affect ADME Clinically significant history current evidence hepatic , renal , gastrointestinal , hematologic abnormality Hepatitis B , hepatitis C , HIV infection reveal laboratory finding Any acute chronic disease A history hypersensitivity donepezil A history alcohol drug abuse Participation another clinical trial within 3 month smoke &gt; 10 cigarette daily consumption 5 glass daily beverage contain xanthine derivative use medication potential affect study result within 10 day start study . AST ALT &gt; 1.25 upper normal limit total bilirubin &gt; 1.5 upper normal limit systolic blood pressure &lt; 90 mmHg calculate CLcr use CockroftGault equation &lt; 50 mL/min</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Benign Prostatic Hyperplasia ( BPH )</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>finasteirde</keyword>
	<keyword>tamsulosin</keyword>
</DOC>